Regeneron Pharmaceuticals (NASDAQ:REGN) Given Sector Perform Rating at Royal Bank Of Canada

Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “sector perform” rating reaffirmed by analysts at Royal Bank Of Canada in a report issued on Tuesday, Benzinga reports. They currently have a $737.00 target price on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price target suggests a potential upside of 0.24% from the company’s current price.

Several other research firms also recently weighed in on REGN. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, September 21st. Guggenheim boosted their target price on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Cantor Fitzgerald boosted their target price on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. HSBC boosted their target price on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Finally, Citigroup boosted their target price on shares of Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the stock a “neutral” rating in a research report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $809.50.

Regeneron Pharmaceuticals Stock Up 0.1%

Shares of Regeneron Pharmaceuticals stock traded up $0.39 on Tuesday, reaching $735.20. The stock had a trading volume of 611,490 shares, compared to its average volume of 830,689. The company has a 50 day moving average price of $786.71 and a 200 day moving average price of $720.83. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals has a 1 year low of $541.00 and a 1 year high of $859.34. The stock has a market capitalization of $75.70 billion, a P/E ratio of 18.17, a P/E/G ratio of 1.49 and a beta of 0.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. The firm had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $12.81 EPS. As a group, equities research analysts forecast that Regeneron Pharmaceuticals will post 44.25 EPS for the current year.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $340,000.00. Following the completion of the transaction, the director directly owned 603 shares in the company, valued at $512,550. The trade was a 39.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the sale, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. The trade was a 31.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 3,946 shares of company stock worth $3,302,458 in the last three months. Company insiders own 6.97% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth $5,682,636,000. State Street Corp increased its holdings in Regeneron Pharmaceuticals by 3.6% in the 2nd quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock worth $3,014,621,000 after acquiring an additional 170,210 shares in the last quarter. Franklin Resources Inc. increased its holdings in Regeneron Pharmaceuticals by 4.4% in the 4th quarter. Franklin Resources Inc. now owns 2,560,004 shares of the biopharmaceutical company’s stock worth $1,975,990,000 after acquiring an additional 106,861 shares in the last quarter. Nuveen LLC increased its holdings in Regeneron Pharmaceuticals by 71.1% in the 4th quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock worth $1,551,858,000 after acquiring an additional 835,240 shares in the last quarter. Finally, Invesco Ltd. increased its holdings in Regeneron Pharmaceuticals by 7.2% in the 4th quarter. Invesco Ltd. now owns 1,591,105 shares of the biopharmaceutical company’s stock worth $1,228,127,000 after acquiring an additional 106,632 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Expanded Sanofi alliance provides substantial near-term and potential long-term value. Regeneron will receive $1 billion upfront and could receive up to $7 billion in milestone payments for adding four next-generation, long-acting antibodies targeting type 2 inflammation. The companies will share development and commercialization costs and future profits, potentially strengthening Regeneron’s immunology pipeline beyond Dupixent. Regeneron and Sanofi Expand Global Alliance
• Positive Sentiment: Trevogrumab delivered promising obesity-treatment data. In the Phase 2 COURAGE trial, the antibody prevented approximately 70% of the lean-mass loss associated with semaglutide in an MRI substudy. The results support a potential combination therapy addressing a key side effect of GLP-1 weight-loss drugs. Phase 2 COURAGE Trial Results
• Positive Sentiment: Analysts became more constructive. Jefferies raised its price target to $930 from $870 and maintained a buy rating, while Argus upgraded REGN to buy with an $850 target. These actions signal confidence in the company’s pipeline and valuation. Regeneron Analyst Price Target Changes
• Neutral Sentiment: Ubamatamab showed encouraging but preliminary efficacy in ovarian cancer. The treatment produced a 73% objective response rate and an 11-month median progression-free survival in 11 heavily pretreated patients with low-grade serous ovarian cancer. The small, early-stage dataset needs confirmation in larger studies. Ubamatamab Ovarian Cancer Results
• Negative Sentiment: The ovarian cancer report initially pressured the stock. Despite the high response rate, investors appeared concerned about the limited sample size, early development stage and uncertainty over whether the results will translate into regulatory approval or commercial revenue. RBC’s “sector perform” rating also provides a more cautious counterpoint to the bullish analyst actions. Regeneron Ovarian Cancer Trial Data

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.